Lombard Medical (EVAR) Misses Q2 EPS by 2c; Revises FY16 Revenue Outlook

Lombard Medical (NASDAQ: EVAR) reported Q2 EPS of ($0.42), $0.02 worse than the analyst estimate of ($0.40). Revenue for the quarter came in at $3.8 million versus the consensus estimate of $3.8 million.

Due to the suspension of the US commercial operation, Lombard feels it is also prudent to amend its revenue guidance for the year to between $13 million and $15 million, driven in the second half by continued procedure and revenue growth in the Company’s go-forward core markets of Europe and Japan.

**** The Street sees FY16 revenue of $17.6 million.

For earnings history and earnings-related data on Lombard Medical (EVAR) click here.

You May Also Be Interested In

• Schlumberger (SLB) earnings in-line, revenue beats expectations
• P&G raises annual core profit forecast on price hikes, easing costs
• Southern First Bancshares, Inc. (SFST) Misses Q1 EPS by 8c